EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Real-World Use of Oral Wegovy and Foundayo: Treatment History, Dose Escalation, and Weight Change in Propensity-Matched Adults

Karthik Murugadoss, A. J. Venkatakrishnan, Christopher J. Gregg, Gowtham Varma, Santhosh Shiv, Marcelo Montorzi, C. Michael Gibson, Venky Soundararajan

Obesities · 14.11.2026 · 6 (6) · 85

DOI: 10.3390/obesities6060085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesities, online erschienen am 14.11.2026. Verfasst von Karthik Murugadoss und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Oral semaglutide (the Wegovy pill; hereafter oral Wegovy) and orforglipron (Foundayo) were recently approved for weight management. We described early routine-care use and explored early weight change.

Methods

We retrospectively analyzed de-identified electronic health records through 21 September 2026 for 16,220 oral Wegovy and 1106 Foundayo recipients. A large language model extracted note content, with physician review of the sample. Propensity matching yielded 756 adults per drug.

Results

Before matching, 56.0% of oral Wegovy and 63.8% of Foundayo recipients had recorded prior incretin exposure (p < 0.001), most still on a submaximal day-90 dose. Of matched patients whose 90-day window had closed (659 and 684), only 26 and 18 contributed a 90-day weight; contributors had more prior-year weight and diagnosis records than non-contributors and differed between drugs, notably in age. In this subset, mean weight change was −3.1% with oral Wegovy and +0.4% with Foundayo (exploratory difference, 3.55 percentage points; 95% CI, 1.02–6.08). Note-derived findings on weight loss/gain, and attendant changes in laboratory values (cholesterol, triglycerides) were nominally consistent with exploratory findings in weight loss, but did not survive multiple-testing correction.

Conclusions

Early use of both pills featured frequent prior incretin exposure and incomplete dose escalation. Weight follow-up was sparse and selected; between-drug weight differences are hypothesis-generating and require confirmation in follow-up work.

Zitieren

APA

Murugadoss, K., Venkatakrishnan, A. J., Gregg, C. J., Varma, G., Shiv, S., Montorzi, M., Gibson, C. M., & Soundararajan, V. (2026). Early Real-World Use of Oral Wegovy and Foundayo: Treatment History, Dose Escalation, and Weight Change in Propensity-Matched Adults. Obesities, 6(6), 85. https://doi.org/10.3390/obesities6060085

Vancouver

Murugadoss K, Venkatakrishnan AJ, Gregg CJ, Varma G, Shiv S, Montorzi M, et al. Early Real-World Use of Oral Wegovy and Foundayo: Treatment History, Dose Escalation, and Weight Change in Propensity-Matched Adults. Obesities. 2026;6(6):85. doi:10.3390/obesities6060085

BibTeX
@article{Murugadoss2026,
  author = {Murugadoss, Karthik and Venkatakrishnan, A. J. and Gregg, Christopher J. and Varma, Gowtham and Shiv, Santhosh and Montorzi, Marcelo and Gibson, C. Michael and Soundararajan, Venky},
  title = {Early Real-World Use of Oral Wegovy and Foundayo: Treatment History, Dose Escalation, and Weight Change in Propensity-Matched Adults},
  journal = {Obesities},
  year = {2026},
  volume = {6},
  number = {6},
  pages = {85},
  doi = {10.3390/obesities6060085}
}
Kostenlos starten →